IP Library Granted Patent US 8,624,079
Granted Patent B2
US 8,624,079 · App. 12/602,723 · Granted Jan 7, 2014

Knockin mouse with a disruption in a PXR gene expressing human PXR

Inventors: Charles Roland Wolf (Dundee, GB); Nico Scheer (Cologne, DE)
Assignee: ITI Scotland Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,624,079
App. No.
12/602,723
Granted
Jan 7, 2014
Kind
B2
Abstract

The present invention relates to transgenic non-human animals, tissues or cells derived therefrom and methods of producing them. The transgenic non-human animals or tissues or cells derived therefrom provide a system capable of expressing human proteins responsible for drug metabolism in place of the homologous endogenous non-human animal proteins and for the controlled expression of human genes introduced into the animal so that the expression of the human genes is regulated in a manner more closely analogous to that seen in vivo in humans. One aspect of the invention relates to the use of a human DNA sequence comprising at least part of introns 6 and/or 7 of the human PXR gene.

Claims (10)

1. A transgenic mouse, or tissue or cells derived therefrom, whose genome comprises:

(i) an annulled pregnane X receptor transcription factor (PXR) gene; and

(ii) a DNA sequence encoding a human PXR gene knocked-into the mouse PXR locus, wherein:

a. said DNA sequence has an intron-exon structure and comprises at least part of intron 6 and/or intron 7 of the human PXR gene; and

b. expression of the human PXR gene is under the control of a mouse PXR promoter.

2. The transgenic mouse, or tissue or cells derived therefrom according to claim 1 , wherein said human DNA sequence comprises at least part of introns 4, 5, 6, and/or 7 of the human PXR gene.

3. The transgenic mouse, or tissue or cells derived therefrom according to claim 1 , wherein said DNA sequence comprises introns 4-8 of the human PXR gene.

4. The transgenic mouse, or tissue or cells derived therefrom according to claim 1 , wherein said DNA sequence further comprises at least part of introns 2, 3, 6, 7, and/or 8 of the human PXR gene.

5. The transgenic mouse, or tissue or cells derived therefrom according to claim 1 , wherein said human DNA sequence comprises introns 2-8 of the human PXR gene.

6. The transgenic mouse, or tissue or cells derived therefrom according to claim 1 , wherein said human DNA sequence comprises a sequence that is at least 70% identical to the sequence of SEQ ID NO:2 or the sequence of SEQ ID NO:3.

Assignments (3)
SECURITY INTEREST Recorded Nov 1, 2022
From: TACONIC BIOSCIENCES, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061608/0403 →
ASSIGNATION AND LISCENSE TERMINATION Recorded Oct 21, 2022
From: ITI SCOTLAND LIMITED
To: TACONIC BIOSCIENCES, INC.
Reel/Frame 061740/0602 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2010
From: WOLF, CHARLES ROLAND; SCHEER, NICO
To: ITI SCOTLAND LIMITED
Reel/Frame 024535/0014 →
Continuity (2)
Continuation In Part 11757972 · Jun 4, 2007
Related Publication 20100257620A1 · Oct 7, 2010